剖宫产史与葡萄胎后妊娠滋养细胞肿瘤风险的关联追踪
这项回顾性队列研究纳入巴西和美国两个妊娠滋养细胞疾病参考中心2002年1月至2022年12月组织病理学确诊的2904例葡萄胎患者,按既往有无剖宫产分组。多因素logistic回归显示,剖宫产史与葡萄胎后妊娠滋养细胞肿瘤风险增加相关(aOR 1.45,95% CI 1.13-1.85);在621例低危妊娠滋养细胞肿瘤患者中,剖宫产史与化疗耐药无显著关联。
要点
- 剖宫产史使葡萄胎后妊娠滋养细胞肿瘤风险增加45.0%(aOR 1.45,95% CI 1.13-1.85)。
- 既往剖宫产次数及择期指征未显著改变该风险。
- 剖宫产史与低危妊娠滋养细胞肿瘤化疗耐药无显著关联。
核心结论
- 剖宫产史与葡萄胎后妊娠滋养细胞肿瘤风险增加45.0%相关,但无证据表明化疗耐药性增加。
- 研究结果支持现行管理方案,同时提示有剖宫产史的患者在标准葡萄胎后监测中可能需要加强临床警惕。
研究设计与样本
- 回顾性队列研究,涉及巴西和美国两个妊娠滋养细胞疾病参考中心。
- 纳入2002年1月至2022年12月组织病理学确诊的葡萄胎患者2904例,按既往有无剖宫产分组。
- 主要结局为葡萄胎后妊娠滋养细胞肿瘤发生,次要结局为单药化疗耐药;采用多因素logistic回归调整相关混杂因素。
主要发现
- 在2904例葡萄胎患者中,剖宫产史与葡萄胎后妊娠滋养细胞肿瘤风险增加独立相关(aOR 1.45,95% CI 1.13-1.85),独立于年龄、完全性葡萄胎组织学、清宫城市、清宫前hCG水平及葡萄胎诊断年份。
- 既往剖宫产次数(aOR 1.43,95% CI 0.91-2.24)及择期指征(aOR 1.12,95% CI 0.60-2.08)未显著改变该风险。
- 在621例低危妊娠滋养细胞肿瘤患者中,剖宫产史(aOR 1.27,95% CI 0.59-2.73)、既往剖宫产次数(aOR 0.22,95% CI 0.02-1.89)及指征(aOR 0.36,95% CI 0.06-2.03)与化疗耐药无显著关联。
临床怎么用
- 有剖宫产史的葡萄胎患者可按现行标准方案管理,但标准葡萄胎后监测中应加强临床警惕。
- 剖宫产史不作为预测化疗耐药的依据,低危妊娠滋养细胞肿瘤化疗耐药风险评估无需因此改变。
局限性
- 回顾性队列设计,可能存在未测量混杂。
- 研究限于两个参考中心,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether the history of cesarean delivery influences the risk or clinical aggressiveness of postmolar gestational trophoblastic neoplasia. METHODS: This retrospective cohort study involved two gestational trophoblastic disease reference centers in Brazil and the United States. Medical records from patients with histopathologically confirmed hydatidiform mole between January 2002 and December 2022 were reviewed. Patients were grouped according to the presence or absence of prior cesarean delivery. The primary outcome was the development of postmolar gestational trophoblastic neoplasia; the secondary outcome was resistance to single-agent chemotherapy. Multivariable logistic regression models adjusted for relevant confounders were used to identify independent predictors. RESULTS: Among 2,904 patients with hydatidiform mole, prior cesarean delivery was associated in a multivariable logistic regression with an increased risk of postmolar gestational trophoblastic neoplasia (adjusted odds ratio [aOR] 1.45, 95% CI, 1.13-1.85) that was independent of age, complete hydatidiform mole histology, city of uterine evacuation, pre-evacuation human chorionic gonadotropin level, and year of hydatidiform mole diagnosis. Furthermore, neither the number of previous cesarean deliveries (aOR 1.43, 95% CI, 0.91-2.24) nor an elective indication (aOR 1.12, 95% CI, 0.60-2.08) appeared to modify this risk. Cesarean delivery history (aOR 1.27, 95% CI, 0.59-2.73) and number of (aOR 0.22, 95% CI, 0.02-1.89) or indication for (aOR 0.36, 95% CI, 0.06-2.03) prior cesarean delivery were not significantly associated with chemoresistance among 621 patients with low-risk gestational trophoblastic neoplasia. CONCLUSION: A history of cesarean delivery is associated with a 45.0% increased risk of postmolar gestational trophoblastic neoplasia without evidence of greater chemoresistance. These findings support current management protocols while indicating that patients with prior cesarean delivery may benefit from heightened clinical vigilance during standard postmolar surveillance.
引用
- Paiva G, Braga A, Artimos de Oliveira S, et al. Tracking the Cesarean Delivery-Postmolar Gestational Trophoblastic Neoplasia Link. Obstet Gynecol. 2026. PMID: 41712926. doi:10.1097/AOG.0000000000006196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。